The modification of certain genes (for example, MLH1) is associated with susceptibility to IBD and hereditary nonpolyposis colorectal cancer (HNPCC; a syndrome associated with familial inheritance of malignancy); therefore, a shift in the treatment of patients with breast malignancies towards a more targeted, immunopathological approach has been observed in recent years [14, 15]. This evidence concerns the gene MLH1 and hereditary nonpolyposis colon cancer.